Needle-free insulin delivery system begins clinical trials
WEST CONSHOHOCKEN, Pa. - Dermisonics on November 16 announced the launch of clinical trials to test its U-Strip Insulin Patch for skin sensitivity on patients with Type 2 diabetes. The patch is designed as a pain-free alternative insulin delivery method for the 55 million insulin users worldwide. The patches will be loaded with 150 units of Eli Lilly's Humalog insulin. The study will also focus on potential unique skin characteristics of diabetics. The insulin delivery market is estimated at $5.4 billion worldwide. Dermisonics is also developing a transdermal application for insulin-dependent cats and dogs.